Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Phase 4

Preoperative Clindamycin Vaginal Cream Versus Vaginal Cleansing With Povidone-iodine on Postoperative Infections After Cesarean Section

NCT07474194 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 4
Started
2025-09-20
Last updated
2026-03-16

Condition(s) studied

Infection Control / MethodsSurgical Site Infection (SSI)

Investigational drug(s) / intervention(s)

Clindamycin vaginal creamVaginal preparation with povidone- iodide solution 10 %

Clindamycin vaginal cream: Clindamycin vaginal cream one applicator each night for 3 nights before CS.

Vaginal preparation with povidone- iodide solution 10 %: Vaginal preparation with povidone- iodide solution 10 %

Study summary

To evaluate the effects of preoperative prophylactic administration of clindamycin vaginal cream compared to preoperative vaginal cleansing using a 10% povidone-iodine solution on postpartum infectious morbidity.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * female participants with singleton pregnancies scheduled for elective cesarean sections at term, specifically between 37 and 40 weeks of gestation * free from any medical disorders. * The participants' ages ranged from 18 to 40 years * body mass index (BMI) ranged from 18 to 30 kg/m2 Exclusion Criteria: 1. Cases of urgent or emergent CS. 2. Abnormal vaginal secretion (bad smelling yellowish secretion, whitish cheesy discharge with pruritus, bloody discharge; etc…). 3. Women with medical disorders such as pre-gestational diabetes, anemia, hypertension, preeclampsia, or immunosuppressant pregnant women. 4. Women who had a skin infection adjacent to the operative site. 5. Allergy to topical povidone-iodine or clindamycin 6. Feverish patients or history of premature rupture of membranes or with placenta previa. 7. patients lost during follow-up were excluded from the final analysis.

Primary outcome measure(s)

  • Wound infection (surgical site infection SSI) — 3 weeks
    erythema, tenderness or wound edge separation with purulent discharge involving the cesarean incision site.

Trial sites (1)

FacilityCityRegionStatus
Beni suef university Banī Suwayf Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07474194 on ClinicalTrials.gov ↗ ← All trials in Egypt